186 related articles for article (PubMed ID: 14576519)
1. Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs.
Vilaine JP; Bidouard JP; Lesage L; Reure H; Péglion JL
J Cardiovasc Pharmacol; 2003 Nov; 42(5):688-96. PubMed ID: 14576519
[TBL] [Abstract][Full Text] [Related]
2. The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease.
Vilaine JP
Pharmacol Res; 2006 May; 53(5):424-34. PubMed ID: 16638639
[TBL] [Abstract][Full Text] [Related]
3. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning.
Monnet X; Ghaleh B; Colin P; de Curzon OP; Giudicelli JF; Berdeaux A
J Pharmacol Exp Ther; 2001 Dec; 299(3):1133-9. PubMed ID: 11714904
[TBL] [Abstract][Full Text] [Related]
4. Heart rate reduction during exercise-induced myocardial ischaemia and stunning.
Monnet X; Colin P; Ghaleh B; Hittinger L; Giudicelli JF; Berdeaux A
Eur Heart J; 2004 Apr; 25(7):579-86. PubMed ID: 15120055
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise.
Joannides R; Moore N; Iacob M; Compagnon P; Lerebours G; Menard JF; Thuillez C
Br J Clin Pharmacol; 2006 Feb; 61(2):127-37. PubMed ID: 16433867
[TBL] [Abstract][Full Text] [Related]
6. Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction.
Heusch G; Kleinbongard P
Drugs; 2016 May; 76(7):733-40. PubMed ID: 27041289
[TBL] [Abstract][Full Text] [Related]
7. Chronic reduction of myocardial ischemia does not attenuate coronary collateral development in miniswine.
Symons JD; Pitsillides KF; Longhurst JC
Circulation; 1992 Aug; 86(2):660-71. PubMed ID: 1638730
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise.
Colin P; Ghaleh B; Hittinger L; Monnet X; Slama M; Giudicelli JF; Berdeaux A
Am J Physiol Heart Circ Physiol; 2002 Feb; 282(2):H672-9. PubMed ID: 11788417
[TBL] [Abstract][Full Text] [Related]
9. [The discovery of the selective If current inhibitor ivabradine (Procoralan): a new therapeutic approach to ischemic heart disease].
Vilaine JP
Med Sci (Paris); 2006 Jan; 22(1):87-94. PubMed ID: 16386229
[TBL] [Abstract][Full Text] [Related]
10. Ivabradine: cardiovascular effects.
Rognoni A; Bertolazzi M; Macciò S; Rognoni G
Recent Pat Cardiovasc Drug Discov; 2009 Jan; 4(1):61-6. PubMed ID: 19149708
[TBL] [Abstract][Full Text] [Related]
11. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction.
Heusch G; Skyschally A; Gres P; van Caster P; Schilawa D; Schulz R
Eur Heart J; 2008 Sep; 29(18):2265-75. PubMed ID: 18621770
[TBL] [Abstract][Full Text] [Related]
12. Ivabradine: an intelligent drug for the treatment of ischemic heart disease.
Riccioni G
Molecules; 2012 Nov; 17(11):13592-604. PubMed ID: 23159921
[TBL] [Abstract][Full Text] [Related]
13. Ivabradine induces an increase in ventricular fibrillation threshold during acute myocardial ischemia: an experimental study.
Vaillant F; Timour Q; Descotes J; Manati W; Belhani D; Bui-Xuan B; Tabib A; Bricca G; Chevalier P
J Cardiovasc Pharmacol; 2008 Dec; 52(6):548-54. PubMed ID: 19034029
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the haemodynamic effects of the selective bradycardic agent UL-FS 49, with those of propranolol during treadmill exercise in dogs.
Krumpl G; Winkler M; Schneider W; Raberger G
Br J Pharmacol; 1988 May; 94(1):55-64. PubMed ID: 3401644
[TBL] [Abstract][Full Text] [Related]
15. Bradycardic agent UL-FS 49 attenuates ischemic regional myocardial dysfunction and reduces infarct size in swine: comparison with the beta-blocker atenolol.
Schulz R; Rose J; Skyschally A; Heusch G
J Cardiovasc Pharmacol; 1995 Feb; 25(2):216-28. PubMed ID: 7752647
[TBL] [Abstract][Full Text] [Related]
16. Ranolazine and Ivabradine: two different modalities to act against ischemic heart disease.
Cacciapuoti F
Ther Adv Cardiovasc Dis; 2016 Apr; 10(2):98-102. PubMed ID: 26944071
[TBL] [Abstract][Full Text] [Related]
17. Propranolol ameliorates exercise-induced regional myocardial dysfunction in dogs.
Mayer N; Krumpl G; Schneider W; Raberger G
Clin Exp Pharmacol Physiol; 1986; 13(11-12):791-9. PubMed ID: 3829447
[TBL] [Abstract][Full Text] [Related]
18. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.
Ruzyllo W; Tendera M; Ford I; Fox KM
Drugs; 2007; 67(3):393-405. PubMed ID: 17335297
[TBL] [Abstract][Full Text] [Related]
19. Preclinical results with I(f) current inhibition by ivabradine.
Berdeaux A
Drugs; 2007; 67 Suppl 2():25-33. PubMed ID: 17999561
[TBL] [Abstract][Full Text] [Related]
20. [A New Insight on Anti-Ischemic Action of Ivabradine in Patients With Stable Angina].
Kobalava ZD; Shavarov AA; Kiyakbaev GK
Kardiologiia; 2017 Mar; 57(3):68-74. PubMed ID: 28762939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
